[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oocyte-competence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oocyte-competence":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100564483","the-epic-study-exploring-paternal-age-and-the-influence-on-blastocyst-culture-100564483",false,"NCT06629766","The EPIC Study: Exploring Paternal Age and the Influence on Blastocyst Culture","EPIC","Inclusion Criteria:\n\n* Undergoing first IVF cycle\n* Electing single embryo transfer\n* Electing PGT-A of their embryos\n* Female partners age \\\u003C42 years old at start of VOR cycle, but \\>18 years old.\n* AMH ≥ 1.2 ng\u002FmL\n* AFC ≥ 8\n* FSH ≤ 12IU\u002FL\n* At least 4 mature oocytes (M2s) retrieved at the VOR procedure in order to randomize\n* Intention to transfer the morphological best quality, euploid, embryo at the frozen embryo transfer procedure\n\nExclusion Criteria:\n\n* Contraindication to IVF\n* Clinical indication for preimplantation genetic testing (i.e., screening for single gene disorder, chromosomal translocation, or any other disorders requiring a more detailed embryo genetic analysis)\n* Male partner with azoospermia or oligozoospermia (\\\u003C500,000 total motile spermatozoa on the most recent semen analysis within one year of enrollment)\n* Planned for previously cryopreserved sperm to be used for ICSI\n* Donor sperm\n* Male partner with Y-chromosome microdeletion\n* Male partner with any Karyotype other than 46,XY\n* Male partner requiring surgically obtained sperm either via testicular or epididymal retrieval procedures\n* Uncorrected hydrosalpinges that communicate with the endometrial cavity\n* Endometrial Insufficiency, as defined by a prior cycle with maximal endometrial thickness \\\u003C6mm,), or persistent endometrial fluid\n* Donor oocyte or embryo cycles\n* Gestational carriers","FEMALE","18 Years","41 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to assess the effect of age of the male partner and the reproductive ability of sperm prepared via sperm selection devices (Zymot) compared to routine embryologist selected sperm after density gradient centrifugation (DGC) preparation for intracytoplasmic sperm injection (ICSI) in patients undergoing in vitro fertilization treatment (IVF) of their infertility.",[27,28,29,30,31],"Infertility (IVF Patients)","Oocyte Competence","Sperm DNA Fragmentation","Paternal Age","Sperm Selection",[33,34,35,36,37,38],"microfluidic","density grade centrifugation","sperm selection","paternal age","sperm DNA fragmentation","Zymot","RECRUITING","2026-06-01",{"date":42,"type":43},"2026-06-03","ACTUAL",{"date":45,"type":43},"2025-04-09",{"date":47,"type":21},"2028-12",{"name":49,"class":50},"Reproductive Medicine Associates of New Jersey","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":51},"100598036","adipose-stem-cell-mitochondria-supplementation-to-oocytes-ascent-100598036","NCT07066267","Adipose Stem Cell Mitochondria Supplementation to Oocytes (ASCENT)","Clinical Application of Autologous Adipose Stem Mitochondria Transplantation to Oocytes for Improving Embryo Quality in Patients With Recurrent Pregnancy Failure","Inclusion Criteria:\n\n* Having at least three previous failed IVF trial\n* Specifically consented for to collect biopsies for Preimplantation generic testing for aneuploidy (PGTA) analysis\n* Specifically consented for to have single blastocyst transfer (recommended)\n* No major uterine or ovarian abnormalities\n* Specifically consented for to have all embryos frozen\n* Specifically consented for to collect adipose tissues from subcutaneous liposuction\n* BMI level level \\\u003C26kg\u002Fm2\n\nExclusion Criteria:\n\n* Ovarian endometriosis with Chocolate cysts (American Fertility Society (AFS)) classification type 3 and 4\n* Any medical contraindication oocyte retrieval or subsequent procedures Ovarian hyperstimulation syndrome Bleeding disorders Sex hormone allergies Severe emotional defect on injections\n* Severe sperm abnormalities\n* \\\u003C5 million\u002FmL motile sperm\n* Uterine structural anomalies\n* Polycystic ovaries\n* Premature ovarian failure","29 Years","39 Years",{"count":62,"type":21},20,[24],"The purpose of this study is to investigate the potential of autologous adipose stem cell (ASC) mitochondrial transfer (ASCENT) to oocytes along with intracytoplasmic sperm injection (ICSI)as a means of enhancing embryo development and improving the success rate of in patients with a history of multiple IVF failures. Embryo quality plays a crucial role in determining the success of assisted reproductive technologies and directly contributes to repeated pregnancy failures. Several factors, including age, physiological conditions, genetics, and environmental influences, can significantly impact embryo quality. Oocytes, the largest cells in the human body, are heavily reliant on mitochondria. Mitochondria's role in providing energy for oocytes is crucial, and insufficient energy production has been linked to poor oocyte and embryo quality. Some human studies have shown that increasing oocyte mitochondrial mass can improve embryo quality in patients who have experienced repeated IVF failures.",[66,28,67,68,69],"Female Infertility","Mitochondria","Recurent Implantation Failures","Advanced Age",[71,72,73,74,75],"mitochondria","mitochondria transplantation","Adipose stem cell","oocyte","Female infertility","2025-07-14",{"date":78,"type":43},"2025-07-17",{"date":80,"type":43},"2025-04-25",{"date":82,"type":21},"2026-12-31",{"name":84,"class":85},"Sunkaky Medical Cooperation","INDUSTRY"]